Annals of African Medicine
Home About AAM Editorial board Ahead of print Current Issue Archives Instructions Subscribe Contact us Search Login 


 
Table of Contents
REVIEW ARTICLE
Year : 2019  |  Volume : 18  |  Issue : 3  |  Page : 121-126  

Inflammation and cancer


1 Department of Pedodontics and Preventive Dentistry, Chandra Dental College and Hospital, Safedabad, Barabanki, Uttar Pradesh, India
2 Department of Conservative and Endodontics, P.S.M Dental College and Research Centre, Akkikavu, Thrissur, Kerala, India
3 Department of Oral Pathology and Microbiology, Hi-Tech Dental College and Hospital, Bhubaneswar, Odisha, India
4 Department of Oral and Maxillofacial Surgery, School of Dental Sciences, Krishna Institute of Health Sciences Deemed to be University, Karad, Maharashtra, India
5 Department of Oral Pathology and Microbiology, Tatyasaheb Kore Dental College and Research Centre, New Pargaon, Kolhapur, Maharashtra, India
6 Department of Oral Medicine and Radiology, Tatyasaheb Kore Dental College and Research Centre, New Pargaon, Kolhapur, Maharashtra, India

Date of Web Publication14-Aug-2019

Correspondence Address:
Dr. Nitin Singh
Chandra Dental College and Hospital, Safedabad, Barabanki, UP
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/aam.aam_56_18

Rights and Permissions
   Abstract 


Inflammation is often associated with the development and progression of cancer. The cells responsible for cancer-associated inflammation are genetically stable and thus are not subjected to rapid emergence of drug resistance; therefore, the targeting of inflammation represents an attractive strategy both for cancer prevention and for cancer therapy. Tumor-extrinsic inflammation is caused by many factors, including bacterial and viral infections, autoimmune diseases, obesity, tobacco smoking, asbestos exposure, and excessive alcohol consumption, all of which increase cancer risk and stimulate malignant progression. In contrast, cancer-intrinsic or cancer-elicited inflammation can be triggered by cancer-initiating mutations and can contribute to malignant progression through the recruitment and activation of inflammatory cells. Both extrinsic and intrinsic inflammations can result in immunosuppression, thereby providing a preferred background for tumor development. The current review provides a link between inflammation and cancer development.

   Abstract in French 

Résumé
L'inflammation est souvent associée au développement et à la progression du cancer. Les cellules responsables de l'inflammation associée au cancer sont génétiquement stables et ne subissent donc pas l'émergence rapide d'une pharmacorésistance; par conséquent, le ciblage de l'inflammation représente une stratégie attrayante à la fois pour la prévention du cancer et pour le traitement du cancer. L'inflammation tumorale extrinsèque est causée par de nombreux facteurs, notamment: infections bactériennes et virales, maladies auto-immunes, obésité, tabagisme, exposition à l'amiante et consommation excessive d'alcool, le tout qui augmentent le risque de cancer et stimulent la progression maligne. En revanche, l'inflammation intrinsèque au cancer ou provoquée par le cancer peut être déclenchée par des mutations initiant un cancer et peuvent contribuer à la progression maligne par le recrutement et l'activation de cellules inflammatoires. Tous les deux les inflammations extrinsèques et intrinsèques peuvent entraîner une immunosuppression, fournissant ainsi un fond préféré pour le développement de la tumeur. le l'examen actuel établit un lien entre l'inflammation et le développement du cancer.

Keywords: Cancer, cells, inflammation


How to cite this article:
Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med 2019;18:121-6

How to cite this URL:
Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med [serial online] 2019 [cited 2021 Dec 6];18:121-6. Available from: https://www.annalsafrmed.org/text.asp?2019/18/3/121/264320




   Introduction Top


The presence of leukocytes within tumors, observed in the 19th century by Rudolf Virchow, provided the first indication of a possible link between inflammation and cancer. Yet, it is only during the past decade that clear evidence has been obtained that inflammation plays a critical role in tumorigenesis.[1]

However, when inflammation becomes chronic or lasts too long, it can prove harmful and may lead to disease. The role of pro-inflammatory cytokines, chemokines, adhesion molecules, and inflammatory enzymes has been linked with chronic inflammation [Figure 1].[2]
Figure 1: Different faces of inflammation and its role in tumorigenesis

Click here to view


Chronic inflammation has been found to mediate a wide variety of diseases, including cardiovascular diseases, cancer, diabetes, arthritis, Alzheimer's disease, pulmonary diseases, and autoimmune diseases.[3]

The current review, however, will be restricted to the role of chronic inflammation in cancer. Chronic inflammation has been linked to various steps involved in tumorgenesis, including cellular transformation, promotion, survival, proliferation, invasion, angiogenesis, and metastasis.[4]

Only a minority of all cancers are caused by germline mutations, whereas the vast majority (90%) are linked to somatic mutations and environmental factors. Many environmental causes of cancer and risk factors are associated with some form of chronic inflammation. Up to 20% of cancers are linked to chronic infections, 30% can be attributed to tobacco smoking and inhaled pollutants (such as silica and asbestos), and 35% can be attributed to dietary factors (20% of cancer burden is linked to obesity).[5]

Recent efforts have shed new light on molecular and cellular circuits linking inflammation and cancer. Two pathways have been schematically identified: in the intrinsic pathway, genetic events causing neoplasia initiate the expression of inflammation-related programs that guide the construction of an inflammatory microenvironment, and in the extrinsic pathway, inflammatory conditions facilitate cancer development.[6]

The triggers of chronic inflammation that increase cancer risk or progression include infections (e.g., Helicobacter pylori for gastric cancer and mucosal lymphoma; papillomavirus and hepatitis viruses for cervical and liver carcinomas, respectively), autoimmune diseases (e.g., inflammatory bowel disease for colon cancer), and inflammatory conditions of uncertain origin (e.g., prostatitis for prostate cancer). Cancer-related inflammation, the seventh hallmark of cancer, links to genetic instability.[7]

It was in 1863 that Rudolf Virchow noted leukocytes in neoplastic tissues and made a connection between inflammation and cancer. He suggested that the “lymphoreticular infiltrate” reflected the origin of cancer at sites of chronic inflammation. Over the past 10 years, our understanding of the inflammatory microenvironment of malignant tissues has supported Virchow's hypothesis, and the links between cancer and inflammation are starting to have implications for prevention and treatment.[8]


   Inflammation and Causes Top


Inflammation is the body's response to tissue damage, caused by physical injury, ischemic injury (caused by an insufficient supply of blood to an organ), infection, exposure to toxins, or other types of trauma. The body's inflammatory response causes cellular changes and immune responses that result in repair of the damaged tissue and cellular proliferation (growth) at the site of the injured tissue. Inflammation can become chronic if the cause of the inflammation persists or certain control mechanisms in charge of shutting down the process fail. When these inflammatory responses become chronic, cell mutation and proliferation can result, often creating an environment that is conducive to the development of cancer. The so-called “perfect storm” is an extreme challenge that cancer patients face. This is true for the onset of cancer but also even more important for the advancement of the disease. Various signaling pathways are key contributors in creating epigenetic changes on the outside of the cell, switching on these internal mutations. Therefore, treating the inflammatory causes is always important.

Chronic inflammation has been linked to various steps involved in tumorigenesis, including cellular transformation, promotion, survival, proliferation, invasion, angiogenesis, and metastasis.


   Cancer Development: An Overview Top


Cancer defines malignant neoplasms characterized by metastatic growth. It may occur in almost every organ and tissue relating to a variety of etiologic factors, such as genomic instability and environmental stress.[9]

However, cancer development is still accepted as a multistep process, during which genetic alterations confer specific types of growth advantages; therefore, it drives the progressive transformation from normal cells to malignant cancer cells. Malignant growth is characterized by several key changes: self-sufficiency of growth signals, insensitivity to antigrowth signals, escaping from apoptosis, unregulated proliferation potential, enhanced angiogenesis, and metastasis. Each of these shifts is complicated and accomplished by combined efforts of various signaling processes. In later discussion, we will find that inflammation may contribute to the formation of these cancer phenotypes.[10]


   Mechanisms for the Association between Inflammation and Cancer Top


Chronic inflammation is characterized by sustained tissue damage, damage-induced cellular proliferation, and tissue repair. Cell proliferation in this context is usually correlated with “metaplasia,” a reversible change in cell type. “Dysplasia,” a disorder of cellular proliferation leading to atypical cell production, follows and is regarded as the previous event of carcinoma because it was usually found adjacent to the site of neoplasm.[11]


   Mutagenic Potential of Inflammation Top


The chronic inflammatory microenvironment is predominated by macrophages. Those macrophages, together with other leukocytes, generate high levels of reactive oxygen and nitrogen species to fight infection.[12] However, in a setting of continuous tissue damage and cellular proliferation, the persistence of these infection-fighting agents is deleterious. They may produce mutagenic agents, such as peroxynitrite, which react with DNA and cause mutations in proliferating epithelial and stroma cells. Macrophages and T-lymphocytes may release tumor necrosis factor-alpha (TNF-α) and macrophage migration inhibitory factor to exacerbate DNA damage.[13]

Migration inhibitory factor impairs p53-dependent protective responses, thus causing the accumulation of oncogenic mutations. Migration inhibitory factor also contributes to tumorigenesis by interfering Rb-E2F pathway.


   Helicobacter Pyloriand Cancer Risk Top


The bacterium H. pylori is known to colonize the human stomach and induce chronic atrophic gastritis, intestinal metaplasia, and gastric cancer. H. pylori infection is a major risk factor for gastric cancer development, which is one of the most challenging malignant diseases worldwide with limited treatments.[14]

The multistep pathogenesis of gastric cancer is the best highlighted by Correa sequence that explains the progressive pathway to gastric cancer characterized by distinct histological changes. This model predicts that infection with H. pylori triggers an inflammatory response resulting in chronic, and then, atrophic, gastritis. This is followed by intestinal metaplasia which can be further classified into complete and incomplete subtypes. At this point, some patients will then proceed to gastric cancer via the intermediate stage of dysplasia [Figure 2].[15]
Figure 2: Correa sequence

Click here to view


The improvement or elimination of atrophy and intestinal metaplasia with H. pylori eradication could potentially inhibit gastric carcinogenesis. It is noteworthy to mention that gastric cancer can still develop even after successful eradication therapy. H. pylori eradication does not result in the regression of all precancerous lesions, which may depend on the degree and extent of preneoplastic changes at the time of eradication.[14]


   Inflammatory Cells in Tumor Microenvironment Top


The inflammatory microenvironment of tumors is characterized by the presence of host leukocytes both in the supporting stroma and in tumor areas.[16] Tumor-infiltrating lymphocytes may contribute to cancer growth and spread and to the immunosuppression associated with malignant disease.

Macrophages

Tumor-associated macrophages (TAM) are a major component of the infiltrate of most, if not all tumors. TAM derives from circulating monocytic precursors and is directed into the tumor by chemoattractant cytokines called chemokines. Many tumor cells also produce cytokines called colony-stimulating factors that prolong the survival of TAM. When appropriately activated, TAM can kill tumor cells or elicit tissue destructive reactions centered on the vascular endothelium. However, TAM also produces growth and angiogenic factors as well as protease enzymes which degrade the extracellular matrix. Hence, TAM can stimulate tumor cell proliferation, promote angiogenesis, and favor invasion and metastasis.[17]

Dendritic cells

Dendritic cells have a crucial role in both the activation of antigen-specific immunity and the maintenance of tolerance, providing a link between innate and adaptive immunity. Tumor-associated dendritic cells (TADCs) usually have an immature phenotype with defective ability to stimulate T-cells.[18]

This distribution of TADC is clearly different from that of TAM, which is evenly scattered in tumor tissue. The immaturity of TADC may reflect lack of effective maturation signals, prompt migration of mature cells to lymph nodes, or the presence of maturation inhibitors. TADC is likely to be poor inducers of effective responses to tumor antigens.

Lymphocytes

Natural killer cells are rare in the tumor microenvironment. The predominant T-cell population has a “memory” phenotype. The cytokine profile of these tumor-infiltrating T-cells has not been studied systematically, but in some tumors (e.g. Kaposi's sarcoma, Hodgkin's disease, bronchial carcinoma, and cervical carcinoma), they produce mainly interleukins (ILs) 4 and 5 and not interferon. IL-4 and 5 are cytokines associated with the T-helper type 2 (Th2) cells, whereas interferon is associated with Th1 responses.[19]


   Key Molecular Players in Linking Inflammation to Cancer Top


To address the details of transition from inflammation to cancers and the further development of inflammation-associated cancers, it is necessary to investigate specific roles of key regulatory molecules involved in this process.

Pro-inflammatory cytokines

The cytokine network of several common tumors is rich in inflammatory cytokines, growth factors, and chemokines but generally lacks cytokines involved in specific and sustained immune responses.[20]

There is now evidence that inflammatory cytokines and chemokines, which can be produced by the tumor cells and/or tumor-associated leukocytes and platelets, may contribute directly to malignant progression. Many cytokines and chemokines are inducible by hypoxia, which is a major physiological difference between tumor and normal tissue. Examples are TNF, IL-1 and 6, and chemokines.

The immune response to tumors is constituted by cytokines produced by tumor cells as well as host stromal cells. Tumor-derived cytokines, such as Fas ligand, vascular endothelial growth factor (VEGF), and transforming growth factor-h, may facilitate the suppression of immune response to tumors. Moreover, inflammatory cytokines have also been reported to facilitate the spectrum of tumor development.[21]

Tumor necrosis factor

TNF is a multifunctional cytokine that plays important roles in diverse cellular events such as cell survival, proliferation, differentiation, and death. As a pro-inflammatory cytokine, TNF is secreted by inflammatory cells, which may be involved in inflammation-associated carcinogenesis. TNF exerts its biological functions through activating distinct signaling pathways such as nuclear factor-κB (NF-κB) and c-Jun N-terminal kinase (JNK). NF-κB is a major cell survival signal that is antiapoptotic while sustained JNK activation contributes to cell death. The crosstalk between the NF-κB and JNK is involved in determining cellular outcomes in response to TNF. TNF is a double-edged sword that could be either pro- or antitumorigenic. On one hand, TNF could be an endogenous tumor promoter because TNF stimulates cancer cells' growth, proliferation, invasion and metastasis, and tumor angiogenesis. On the other hand, TNF could be a cancer killer. The property of TNF in inducing cancer cell death renders it a potential cancer therapeutic.[22]

TNF can be detected in malignant and/or stromal cells in human ovarian, breast, prostate, bladder, and colorectal cancer, lymphomas, and leukemias, often in association with ILs-1 and 6 and macrophage colony-stimulating factor.[23]

Interleukins 1 and 6 in cancer regulation

IL-6 is a pleiotropic cytokine that plays important roles in immune response, inflammation, and hematopoiesis. It is produced by a variety of normal cells including monocytes and macrophages but is also expressed by multiple tumor tissue types, such as breast, prostate, colorectal, and ovarian cancer. IL-6 may also play an important role in various aspects of tumor behavior, including apoptosis, tumor growth cell proliferation, migration and invasion, angiogenesis, and metastasis.[24]

IL-10, initially termed “cytokine synthesis inhibitor” or “cytokine inhibitory factor” due to its inhibitory action on cytokine production by T helper cells, is produced by almost all leukocytes, as well as numerous human tumor cells including breast, kidney, colon, pancreas, malignant melanomas, and neuroblastomas. IL-10 is essential to suppress tumor-promoting inflammation mediators, thereby facilitating tumor growth and metastasis. Specifically, TAMs produce IL-10 and are also associated with in-tumor immunosuppression, thereby providing a suitable microenvironment for cancer growth.[25]

In mouse models of metastasis, treatment with an IL-1 receptor antagonist (which inhibits the action of IL-1) significantly decreased tumor development, suggesting that local production of this cytokine aids the development of metastasis. Moreover, mice deficient in IL-1 were resistant to the development of experimental metastasis.[26]

Chemokines

Inflammatory cytokines are major inducers of a family of chemoattractant cytokines called chemokines that play a central role in leukocyte recruitment to sites of inflammation. Most tumors produce chemokines of the two major groups α (or CXC) and β.

Typically, CXC chemokines are active on neutrophils and lymphocytes, whereas CC chemokines act on several leukocyte subsets including monocytes, eosinophils, dendritic cells, lymphocytes, and natural killer cells but not neutrophils.[27]

Human and murine tumors also frequently secrete CXC chemokines such as IL-8. These chemokines are potent neutrophil attractants, yet neutrophils are rare in tumors. However, both IL-8 and a related chemokine called “gro” induce proliferation and migration of melanoma cell.


   Implications for Prevention and Treatment Top


Tumor necrosis factor blockade

TNF antagonists (etanercept [Enbrel] and infliximab [Remicade]) have been licensed for a clinical trial in the treatment of rheumatoid arthritis and Crohn's disease, with over 70,000 patients now treated. Thalidomide inhibits the processing of mRNA for TNF and VEGF, and continuous low-dose thalidomide has shown activity in patients with advanced myeloma. The role of etanercept in ameliorating the adverse effects of other cancer therapies is also being evaluated. There are also ongoing and planned clinical trials with infliximab. As with other “biological” approaches to cancer treatment, anti-TNF therapy may be optimal in an adjuvant setting with minimal disease.[28]

Chemokine antagonism

Chemokine receptors belong to a family of receptors (transmembrane G-protein-coupled receptors) which is already a target of pharmacological interest. Tumors driven by chemokines and those where chemokines are implicated in metastasis (e.g. seeding to lymph nodes) may be an appropriate target for chemokine antagonists now under development.[29]

IL-6 is a major growth factor for myeloma cells. In advanced disease, there is an excess of IL-6 production, and raised serum concentrations are associated with plasmablastic proliferative activity and short survival.

Nonsteroidal anti-inflammatory agents

Nonsteroidal anti-inflammatory drugs (NSAIDs) are nonselective or selective COX-1/2 inhibitors, which are wildly prescribed for pain killing, fever reduction, and even anti-inflammation.

Patients on NSAIDs are at reduced risk of colon cancer. This may also be true for cancers of the esophagus, stomach, and rectum, and in rodents experimental bladder, breast, and colon cancer. Colon cancer is reduced when NSAIDs are administered concurrently with carcinogens. NSAIDs inhibit cyclooxygenase enzymes and angiogenesis.[30]

The mechanisms involved in the association between NSAIDs and distant metastasis inhibition remain incompletely investigated. One possible explanation is that NSAIDs inhibit COX2. Abnormally high COX2 expression is observed in multicancers. Disordered COX2/PGE pathway is involved in multicancer processes, including carcinogenesis, proliferation, and metastatic spread; in addition, inhibition of COX2/PGE pathway with NSAIDs can restrain cancer cell lines.

Mutual promotion relationship between cancer metastasis and cancer-associated thrombosis is possibly another one of the underlying mechanisms. Abnormally high constitutive level of tissue factor (TF), one key regulator of hemostasis, is expressed by metastatic cancer cells, cancer microparticles, and cancer-associated monocytes and macrophages. TF can promote thrombosis formation by activating the extrinsic pathway of coagulation cascade. Furthermore, inflammation induced by thrombosis could result in endothelial damage that results in the vascular leak, facilitating the escape of cancer cells from blood vessels. Consequently, NSAIDs may disrupt the relationship between cancer metastasis and cancer-associated thrombosis via the suppression of platelet function, which is detrimental for the disseminated cancer cells in the bloodstream.[31]


   Conclusion Top


Overall, this review provides evidence for a strong link between chronic inflammation and cancer. Thus, inflammatory biomarkers as described here can be used to monitor the progression of the disease. These biomarkers can also be exploited to develop new anti-inflammatory drugs to prevent and treat cancer. These drugs can also be used as an adjuvant to the currently available chemotherapy and radiotherapy, which by themselves activate NF-κB and mediate resistance. Numerous anti-inflammatory agents including those identified from natural sources have been shown to exhibit chemopreventive activities.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-6.  Back to cited text no. 1
    
2.
Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: How hot is the link? Biochem Pharmacol 2006;72:1605-21.  Back to cited text no. 2
    
3.
Aggarwal BB. Nuclear factor-kappaB: The enemy within. Cancer Cell 2004;6:203-8.  Back to cited text no. 3
    
4.
Mantovani A. Cancer: Inflammation by remote control. Nature 2005;435:752-3.  Back to cited text no. 4
    
5.
Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.  Back to cited text no. 5
    
6.
Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: Short-term friend, long-term foe. Clin Cancer Res 2009;15:425-30.  Back to cited text no. 6
    
7.
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.  Back to cited text no. 7
    
8.
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 2009;30:1073-81.  Back to cited text no. 8
    
9.
Balkwill F, Mantovani A. Inflammation and cancer: Back to virchow? Lancet 2001;357:539-45.  Back to cited text no. 9
    
10.
Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004;14:433-9.  Back to cited text no. 10
    
11.
Cordon-Cardo C, Prives C. At the crossroads of inflammation and tumorigenesis. J Exp Med 1999;190:1367-70.  Back to cited text no. 11
    
12.
Maeda H, Akaike T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Mosc) 1998;63:854-65.  Back to cited text no. 12
    
13.
Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-8.  Back to cited text no. 13
    
14.
Lu B, Li M. Helicobacter pylori eradication for preventing gastric cancer. World J Gastroenterol 2014;20:5660-5.  Back to cited text no. 14
    
15.
Busuttil RA, Zapparoli GV, Haupt S, Fennell C, Wong SQ, Pang JM, et al. Role of p53 in the progression of gastric cancer. Oncotarget 2014;5:12016-26.  Back to cited text no. 15
    
16.
Negus RP, Stamp GW, Hadley J, Balkwill FR. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 1997;150:1723-34.  Back to cited text no. 16
    
17.
Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol Today 1992;13:265-70.  Back to cited text no. 17
    
18.
Allavena P, Sica A, Vecchi A, Locati M, Sozzani S, Mantovani A. The chemokine receptor switch paradigm and dendritic cell migration: Its significance in tumor tissues. Immunol Rev 2000;177:141-9.  Back to cited text no. 18
    
19.
Burke F, Relf M, Negus R, Balkwill F. A cytokine profile of normal and malignant ovary. Cytokine 1996;8:578-85.  Back to cited text no. 19
    
20.
Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004;202:275-93.  Back to cited text no. 20
    
21.
Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 1993;91:2194-206.  Back to cited text no. 21
    
22.
Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin 2008;29:1275-88.  Back to cited text no. 22
    
23.
Vidal-Vanaclocha F, Fantuzzi G, Mendoza L, Fuentes AM, Anasagasti MJ, Martín J, et al. IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci U S A 2000;97:734-9.  Back to cited text no. 23
    
24.
Hassuneh MR, Nagarkatti M, Nagarkatti PS. Role of interleukin-10 in the regulation of tumorigenicity of a T cell lymphoma. Leuk Lymphoma 2013;54:827-34.  Back to cited text no. 24
    
25.
Ahmad N, Ammar A, Storr SJ, Green AR, Rakha E, Ellis IO, et al. IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients. Cancer Immunol Immunother 2018;67:537-49.  Back to cited text no. 25
    
26.
Negus RP, Stamp GW, Relf MG, Burke F, Malik ST, Bernasconi S, et al. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest 1995;95:2391-6.  Back to cited text no. 26
    
27.
Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000;51:207-29.  Back to cited text no. 27
    
28.
Haghnegahdar H, Du J, Wang D, Strieter RM, Burdick MD, Nanney LB, et al. The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. J Leukoc Biol 2000;67:53-62.  Back to cited text no. 28
    
29.
Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000;355:248-50.  Back to cited text no. 29
    
30.
Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-7.  Back to cited text no. 30
    
31.
Zhao X, Xu Z, Li H. NSAIDs use and reduced metastasis in cancer patients: Results from a meta-analysis. Sci Rep 2017;7:1875.  Back to cited text no. 31
    


    Figures

  [Figure 1], [Figure 2]


This article has been cited by
1 Calprotectin in viral systemic infections—COVID-19 versus hepatitis C virus
Letitia Toma, Mihai Dodot, Anca Zgura, Nicolae Bacalbasa, Andrei Silaghi, Razvan Simu, Teodora Isac, Adriana Mercan-Stanciu
Clinical and Experimental Medicine. 2021;
[Pubmed] | [DOI]
2 Anti-neoplastic phramacophore benzophenone-1 coumarin (BP-1C) targets JAK2 to induce apoptosis in lung cancer
Ankith Sherapura, Vikas H. Malojirao, Prabhu Thirusangu, B. S. Sharath, Shivananda Kandagalla, V. Vigneshwaran, Jurica Novak, Lakshmi Ranganatha, Y. L. Ramachandra, Shrinath M. Baliga, Shaukath Ara Khanum, B. T. Prabhakar
Apoptosis. 2021;
[Pubmed] | [DOI]
3 Elastin-Derived Peptides in the Central Nervous System: Friend or Foe
Konrad A. Szychowski, Bartosz Skóra, Anna K. Wójtowicz
Cellular and Molecular Neurobiology. 2021;
[Pubmed] | [DOI]
4 Unboxing the molecular modalities of mutagens in cancer
Smita Kumari, Sudhanshu Sharma, Dia Advani, Akanksha Khosla, Pravir Kumar, Rashmi K. Ambasta
Environmental Science and Pollution Research. 2021;
[Pubmed] | [DOI]
5 Cure lies in nature: medicinal plants and endophytic fungi in curbing cancer
Garima Tyagi, Neha Kapoor, Girish Chandra, Lokesh Gambhir
3 Biotech. 2021; 11(6)
[Pubmed] | [DOI]
6 The role of Wnt pathway in obesity induced inflammation and diabetes: a review
Bhabajyoti Das, Manas Das, Anuradha Kalita, Momita Rani Baro
Journal of Diabetes & Metabolic Disorders. 2021;
[Pubmed] | [DOI]
7 Synthesis of 6-epi-tuberiferin and the biological activities of tuberiferin, dehydrobrabrachylaenolide, 6-epi-tuberiferin, and their synthetic intermediates
Dan Li, Yohsuke Higuchi, Takafumi Kobayashi, Fumito Shimoma, Yuhua Bai, Masayoshi Ando
Bioorganic Chemistry. 2021; 108: 104642
[Pubmed] | [DOI]
8 The effect of medications associated with drug-induced pancreatitis on pancreatic cancer risk: A nested case-control study of routine Scottish data
R.D. McDowell, C.M. Hughes, P. Murchie, C.R. Cardwell
Cancer Epidemiology. 2021; 71: 101880
[Pubmed] | [DOI]
9 Trans-anethole Attenuates Diet-induced Nonalcoholic Steatohepatitis Through Suppressing TGF-ß-mediated Fibrosis
Caicai Zhang, Baoyong Zhang, Aifang Chen, Qiling Yin, Haixia Wang
Clinics and Research in Hepatology and Gastroenterology. 2021; : 101833
[Pubmed] | [DOI]
10 Long non-coding RNAs regulate the hallmarks of cancer in HPV-induced malignancies
Tânia R. Dias, Joana M.O. Santos, Rui M. Gil da Costa, Rui Medeiros
Critical Reviews in Oncology/Hematology. 2021; 161: 103310
[Pubmed] | [DOI]
11 Analyzing the influence of IL18 in regulation of YAP1 in breast oncogenesis using cBioportal
Ayesha Rahman, Lingadahalli S. Shashidhara
Cancer Reports. 2021;
[Pubmed] | [DOI]
12 Screening and isolation of potential lipoxidase and superoxide dismutase inhibitors from Scutellaria baicalensis Georgi using high-speed countercurrent chromatography target-guided by ultrafiltration-liquid chromatogra
Jianli Xia, Chunming Liu, Huazhou Niu, Wanchao Hou, Sainan Li
Journal of Separation Science. 2021; 44(7): 1371
[Pubmed] | [DOI]
13 Comprehensive analysis reveals common DNA methylation patterns of tobacco-associated cancers: A pan-cancer analysis
Xingyu Liu, Jiarui Chen, Jiali Li, Zihang Zeng, Xueping Jiang, Yanping Gao, Zhengrong Huang, Qiuji Wu, Yan Gong, Conghua Xie
Gene. 2021; 804: 145900
[Pubmed] | [DOI]
14 The diverse roles of TMEM16A Ca2+-activated Cl- channels in inflammation
Weiliang Bai, Mei Liu, Qinghuan Xiao
Journal of Advanced Research. 2021; 33: 53
[Pubmed] | [DOI]
15 Analgesic and anti-inflammatory articular effects of essential oil and camphor isolated from Ocimum kilimandscharicum Gürke leaves
Elisangela dos Santos, Maicon Matos Leitão, Caren Naomi Aguero Ito, Saulo Euclides Silva-Filho, Arielle Cristina Arena, Francielli Maria de Souza Silva-Comar, Roberto Kenji Nakamura Cuman, Rodrigo Juliano Oliveira, Anelise Samara Nazari Formagio, Cândida Aparecida Leite Kassuya
Journal of Ethnopharmacology. 2021; 269: 113697
[Pubmed] | [DOI]
16 Prognostic value of preoperative inflammatory markers among different molecular subtypes of lower-grade glioma
Zengxin Qi, Jiajun Cai, Xiangda Meng, Shengyong Cai, Chao Tang, Liqin Lang
Journal of Clinical Neuroscience. 2021;
[Pubmed] | [DOI]
17 Is resistin the master link between inflammation and inflammation-related chronic diseases?
Mohammed Taouis, Yacir Benomar
Molecular and Cellular Endocrinology. 2021; 533: 111341
[Pubmed] | [DOI]
18 Human gut-microbiome interplay: Analysis of clinical studies for the emerging roles of diagnostic microbiology in inflammation, oncogenesis and cancer management
Ziyu Jiang, Lingchang Li, Jianan Chen, Guoli Wei, Yi Ji, Xi Chen, Jingbing Liu, Jiege Huo
Infection, Genetics and Evolution. 2021; 93: 104946
[Pubmed] | [DOI]
19 Pancreatitis initiated pancreatic ductal adenocarcinoma: Pathophysiology explaining clinical evidence
Xufeng Tao, Hong Xiang, Yue Pan, Dong Shang, Junchao Guo, Ge Gao, Gary Guishan Xiao
Pharmacological Research. 2021; 168: 105595
[Pubmed] | [DOI]
20 The potentials of carbon monoxide-releasing molecules in cancer treatment: An outlook from ROS biology and medicine
Thi Thuy Tien Vo, Quang Canh Vo, Vo Phuoc Tuan, Yinshen Wee, Hsin-Chung Cheng, I-Ta Lee
Redox Biology. 2021; 46: 102124
[Pubmed] | [DOI]
21 Anticancer Natural Products Targeting Immune Checkpoint Protein Network
Kyung-Soo Chun, Do-Hee Kim, Pawan Kumar Raut, Young-Joon Surh
Seminars in Cancer Biology. 2021;
[Pubmed] | [DOI]
22 How do green and black coffee brews and bioactive interaction with gut microbiome affect its health outcomes? Mining evidence from mechanistic studies, metagenomics and clinical trials
Mohamed A. Farag, Martin von Bergen, Basma M. Saleh, Masun Nabhan Homsi, Mohamed S. Abd El-Al
Trends in Food Science & Technology. 2021; 118: 920
[Pubmed] | [DOI]
23 Nimbolide, a Neem Limonoid, Is a Promising Candidate for the Anticancer Drug Arsenal
Siddavaram Nagini, Ramesh Nivetha, Manikandan Palrasu, Rajakishore Mishra
Journal of Medicinal Chemistry. 2021; 64(7): 3560
[Pubmed] | [DOI]
24 CPAP enhances and maintains chronic inflammation in hepatocytes to promote hepatocarcinogenesis
Ruo-Yu Chen, Chia-Jui Yen, Yih-Jyh Lin, Ju-Ming Wang, Ting-Fen Tasi, Yu-Chuan Huang, Yao-Wen Liu, Hung-Wen Tsai, Ming-Hao Lee, Liang-Yi Hung
Cell Death & Disease. 2021; 12(11)
[Pubmed] | [DOI]
25 The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma
Rathasapa Patarat, Shoji Riku, Pattapon Kunadirek, Natthaya Chuaypen, Pisit Tangkijvanich, Apiwat Mutirangura, Charoenchai Puttipanyalears
Scientific Reports. 2021; 11(1)
[Pubmed] | [DOI]
26 Carbon dots up-regulate heme oxygenase-1 expression towards acute lung injury therapy
Bo Wang, Peipei Liu, Hui Huang, Xiting Wang, Mengling Zhang, Jian Huang, Fang Lu, Jian Chen, Yang Liu, Zhenhui Kang
Journal of Materials Chemistry B. 2021; 9(43): 9005
[Pubmed] | [DOI]
27 Amomum subulatum Induces Apoptosis in Tumor Cells and Reduces Tumor Burden in Experimental Animals via Modulating Pro-Inflammatory Cytokines
Drishya Sudarsanan, Dhanisha Suresh Sulekha, Guruvayoorappan Chandrasekharan
Cancer Investigation. 2021; : 1
[Pubmed] | [DOI]
28 Proteases, protease inhibitors and radiation carcinogenesis
Ann R. Kennedy
International Journal of Radiation Biology. 2021; : 1
[Pubmed] | [DOI]
29 Anti-inflammatory effect of Barringtonia angusta methanol extract is mediated by targeting of Src in the NF-?B signalling pathway
Minkyeong Jo, Jongsung Lee, Han Gyung Kim, Jin Kyeong Kim, Haeyeop Kim, Kon Kuk Shin, Tran The Bach, Sang Mi Eum, Jong Sub Lee, Eui Su Choung, Yoonyong Yang, Kyung-Hee Kim, Gi-Ho Sung, Byong Chul Yoo, Jae Youl Cho
Pharmaceutical Biology. 2021; 59(1): 799
[Pubmed] | [DOI]
30 Small molecule compounds with good anti-inflammatory activity reported in the literature from 01/2009 to 05/2021: a review
Ming Bian, Qian-qian Ma, Yun Wu, Huan-huan Du, Gong Guo-hua
Journal of Enzyme Inhibition and Medicinal Chemistry. 2021; 36(1): 2139
[Pubmed] | [DOI]
31 Mechanism of Kaempferol in Anti-inflammation Based on Network Pharmacology
Ping Qin, Hongmei Wu
IOP Conference Series: Earth and Environmental Science. 2021; 692(3): 032031
[Pubmed] | [DOI]
32 Myosteatosis reduces overall survival in patients with digestive system malignancies: a meta-analysis with trial sequential analysis
Yue Wang, Guangwei Tian, Song Chen, Nan Li
Nutrition Research. 2021; 94: 25
[Pubmed] | [DOI]
33 Molecular mechanisms of anticancer activities of polyphyllin VII
Bashir Ahmad, Shafiq Ur Rehman, Azizullah Azizullah, Muhammad Fiaz Khan, Syed Riaz Ud Din, Manzoor Ahmad, Ashraf Ali, Naeem Tahir, Nasir Azam, Yaser Gamallat, Khalil Ur Rahman, Muhsin Ali, Mohammad Safi, Imran Khan, Samina Qamer, Deog-Hwan Oh
Chemical Biology & Drug Design. 2021; 97(4): 914
[Pubmed] | [DOI]
34 IL-9 and IL-10 Single-Nucleotide Variants and Serum Levels in Age-Related Macular Degeneration in the Caucasian Population
Alvita Vilkeviciute, Dzastina Cebatoriene, Loresa Kriauciuniene, Reda Zemaitiene, Rasa Liutkeviciene, Ayumi Ouchi
Mediators of Inflammation. 2021; 2021: 1
[Pubmed] | [DOI]
35 The Uprising of Mitochondrial DNA Biomarker in Cancer
Siti Zulaikha Nashwa Mohd Khair, Siti Muslihah Abd Radzak, Abdul Aziz Mohamed Yusoff, Jie Mei
Disease Markers. 2021; 2021: 1
[Pubmed] | [DOI]
36 Key Factor Regulating Inflammatory Microenvironment, Metastasis, and Resistance in Breast Cancer: Interleukin-1 Signaling
Fengjie Liu, Lihong Li, Meng Lan, Tengteng Zou, Zhaodi Kong, Tiange Cai, Xiao Yu Wu, Yu Cai, Matilde Otero-Losada
Mediators of Inflammation. 2021; 2021: 1
[Pubmed] | [DOI]
37 The Ratio of Platelets to Lymphocytes Predicts the Prognosis of Metastatic Colorectal Cancer: A Review and Meta-Analysis
Jinming Wang, Jing Li, Sheng Wei, Jie Xu, Xiaohui Jiang, Lei Yang, Nicola Silvestris
Gastroenterology Research and Practice. 2021; 2021: 1
[Pubmed] | [DOI]
38 High pretreatment systemic immune-inflammation index values are associated with diminished short-term success after temporomandibular joint arthrocentesis procedure
Efsun Somay, Busra Yilmaz
BMC Oral Health. 2021; 21(1)
[Pubmed] | [DOI]
39 Construction and prognostic analysis of miRNA-mRNA regulatory network in liver metastasis from colorectal cancer
Ruyun Cai, Qian Lu, Da Wang
World Journal of Surgical Oncology. 2021; 19(1)
[Pubmed] | [DOI]
40 Human amniotic mesenchymal stem cells to promote/suppress cancer: two sides of the same coin
Ameneh Jafari, Mostafa Rezaei-Tavirani, Behrouz Farhadihosseinabadi, Hakimeh Zali, Hassan Niknejad
Stem Cell Research & Therapy. 2021; 12(1)
[Pubmed] | [DOI]
41 Availability of preoperative neutrophil-lymphocyte ratio to predict postoperative delirium after head and neck free-flap reconstruction: A retrospective study
Hirotaka Kinoshita, Junichi Saito, Daiki Takekawa, Tasuku Ohyama, Tetsuya Kushikata, Kazuyoshi Hirota, Peter Dziegielewski
PLOS ONE. 2021; 16(7): e0254654
[Pubmed] | [DOI]
42 Cluster analysis of blood serum inflammation markers of conditionally healthy people
L. V. Androsova, A. N. Simonov, N. V. Ponomareva, T. P. Klyushnik
Medical Immunology (Russia). 2021; 23(2): 293
[Pubmed] | [DOI]
43 Anti-inflammatory activities of arthropod peptides: a systematic review
Ariane Teixeira dos Santos, Gabriela Silva Cruz, Gandhi Rádis Baptista
Journal of Venomous Animals and Toxins including Tropical Diseases. 2021; 27
[Pubmed] | [DOI]
44 The Preoperative Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio Predicts Disease-Free Survival in Resectable Esophageal Squamous Cell Carcinoma
Zhiwei Zheng, Cui Yang, Chun Cai, Huide Zhu
Cancer Management and Research. 2021; Volume 13: 7511
[Pubmed] | [DOI]
45 Supervised Learning Based Systemic Inflammatory Markers Enable Accurate Additional Surgery for pT1NxM0 Colorectal Cancer: A Comparative Analysis of Two Practical Prediction Models for Lymph Node Metastasis
Jinlian Jin, Haiyan Zhou, Shulin Sun, Zhe Tian, Haibing Ren, Jinwu Feng
Cancer Management and Research. 2021; Volume 13: 8967
[Pubmed] | [DOI]
46 Metformin and Malignant Tumors: Not Over the Hill
Weiling Leng, Juan Jiang, Bing Chen, Qinan Wu
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2021; Volume 14: 3673
[Pubmed] | [DOI]
47 Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment
Sylwia Milewska, Katarzyna Niemirowicz-Laskowska, Gabriela Siemiaszko, Piotr Nowicki, Agnieszka Z Wilczewska, Halina Car
International Journal of Nanomedicine. 2021; Volume 16: 6593
[Pubmed] | [DOI]
48 GDC-0575, a CHK1 Inhibitor, Impairs the Development of Colitis and Colitis-Associated Cancer by Inhibiting CCR2+ Macrophage Infiltration in Mice
Min Li, Tianqing Huang, Xiaolan Li, Zhiwei Shi, Yue Sheng, Mimi Hu, Kui Song
OncoTargets and Therapy. 2021; Volume 14: 2661
[Pubmed] | [DOI]
49 Preoperative Serum Hypersensitive-c-Reactive-Protein (Hs-CRP) to Albumin Ratio Predicts Survival in Patients with Luminal B Subtype Breast Cancer
Xiujun Liu, Xiuchun Guo, Zhiqiang Zhang
OncoTargets and Therapy. 2021; Volume 14: 4137
[Pubmed] | [DOI]
50 Pretreatment Systemic Immune-Inflammation Index Predict Needs for Teeth Extractions for Locally Advanced Head and Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy
Busra Yilmaz, Efsun Somay, Ugur Selek, Erkan Topkan
Therapeutics and Clinical Risk Management. 2021; Volume 17: 1113
[Pubmed] | [DOI]
51 Risk Factors Associated with Prostate Cancer
Arslan Habib, Ghulam Jaffar, Malik ShahZaib Khalid, Zahid Hussain, Syeda Wafa Zainab, Zeeshan Ashraf, Atia Haroon, Rimsha Javed, Bilal Khalid, Palwasha Habib
Journal of Drug Delivery and Therapeutics. 2021; 11(2): 188
[Pubmed] | [DOI]
52 The relationship of pre-operative laboratory parameters with endometrial cancer and prognostic factors
Süleyman Serkan KARASIN, Burak AKSELIM
Journal of Surgery and Medicine. 2021; 5(4): 344
[Pubmed] | [DOI]
53 The Role of Tumor Inflammatory Microenvironment in Lung Cancer
Zhaofeng Tan, Haibin Xue, Yuli Sun, Chuanlong Zhang, Yonglei Song, Yuanfu Qi
Frontiers in Pharmacology. 2021; 12
[Pubmed] | [DOI]
54 The Crossroads of Periodontitis and Oral Squamous Cell Carcinoma: Immune Implications and Tumor Promoting Capacities
Omnia Elebyary, Abdelahhad Barbour, Noah Fine, Howard C. Tenenbaum, Michael Glogauer
Frontiers in Oral Health. 2021; 1
[Pubmed] | [DOI]
55 Leptin, Both Bad and Good Actor in Cancer
Carlos Jiménez-Cortegana, Ana López-Saavedra, Flora Sánchez-Jiménez, Antonio Pérez-Pérez, Jesús Castiñeiras, Juan A. Virizuela-Echaburu, Luis de la de la Cruz-Merino, Víctor Sánchez-Margalet
Biomolecules. 2021; 11(6): 913
[Pubmed] | [DOI]
56 From Allergy to Cancer—Clinical Usefulness of Eotaxins
Monika Zajkowska, Barbara Mroczko
Cancers. 2021; 13(1): 128
[Pubmed] | [DOI]
57 Association of Genetic Polymorphisms and Serum Levels of IL-6 and IL-8 with the Prognosis in Children with Neuroblastoma
Silvia Selene Moreno-Guerrero, Arturo Ramírez-Pacheco, Luz María Rocha-Ramírez, Gabriela Hernández-Pliego, Pilar Eguía-Aguilar, María Argelia Escobar-Sánchez, Alfonso Reyes-López, Luis Enrique Juárez-Villegas, Juan José Luis Sienra-Monge
Cancers. 2021; 13(3): 529
[Pubmed] | [DOI]
58 The Role of Bacteria in KSHV Infection and KSHV-Induced Cancers
Ashley Markazi, Wen Meng, Paige M. Bracci, Michael S. McGrath, Shou-Jiang Gao
Cancers. 2021; 13(17): 4269
[Pubmed] | [DOI]
59 Potential of Bioactive Food Components against Gastric Cancer: Insights into Molecular Mechanism and Therapeutic Targets
Seog Young Kang, Dongwon Hwang, Soyoung Shin, Jinju Park, Myoungchan Kim, MD. Hasanur Rahman, Md. Ataur Rahman, Seong-Gyu Ko, Bonglee Kim
Cancers. 2021; 13(18): 4502
[Pubmed] | [DOI]
60 Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer
Maximilian Fleischmann, Georgios Chatzikonstantinou, Emmanouil Fokas, Jörn Wichmann, Hans Christiansen, Klaus Strebhardt, Claus Rödel, Nikolaos Tselis, Franz Rödel
Cancers. 2021; 13(22): 5748
[Pubmed] | [DOI]
61 NUB1 and FAT10 Proteins as Potential Novel Biomarkers in Cancer: A Translational Perspective
Maria Arshad, Nazefah Abdul Hamid, Mun Chiang Chan, Fuad Ismail, Geok Chin Tan, Francesco Pezzella, Ka-Liong Tan
Cells. 2021; 10(9): 2176
[Pubmed] | [DOI]
62 Inflammation and Wnt Signaling: Target for Immunomodulatory Therapy?
Imen Jridi, Kirsten Canté-Barrett, Karin Pike-Overzet, Frank J. T. Staal
Frontiers in Cell and Developmental Biology. 2021; 8
[Pubmed] | [DOI]
63 A Mechanism Leading to Changes in Copy Number Variations Affected by Transcriptional Level Might Be Involved in Evolution, Embryonic Development, Senescence, and Oncogenesis Mediated by Retrotransposons
Yunpeng Sui, Shuanghong Peng
Frontiers in Cell and Developmental Biology. 2021; 9
[Pubmed] | [DOI]
64 Tumor-Associated Extracellular Matrix: How to Be a Potential Aide to Anti-tumor Immunotherapy?
Yingying He, Tao Liu, Shuang Dai, Zihan Xu, Li Wang, Feng Luo
Frontiers in Cell and Developmental Biology. 2021; 9
[Pubmed] | [DOI]
65 Impact of Sexual Activity on the Risk of Male Genital Tumors: A Systematic Review of the Literature
Felice Crocetto, Davide Arcaniolo, Luigi Napolitano, Biagio Barone, Roberto La Rocca, Marco Capece, Vincenzo Francesco Caputo, Ciro Imbimbo, Marco De Sio, Francesco Paolo Calace, Celeste Manfredi
International Journal of Environmental Research and Public Health. 2021; 18(16): 8500
[Pubmed] | [DOI]
66 Molecular Action of Polyphenols in Leukaemia and Their Therapeutic Potential
Hamza A. Alaswad, Amani A. Mahbub, Christine L. Le Maitre, Nicola Jordan-Mahy
International Journal of Molecular Sciences. 2021; 22(6): 3085
[Pubmed] | [DOI]
67 RAAS: A Convergent Player in Ischemic Heart Failure and Cancer
Texali C. Garcia-Garduño, Jorge R. Padilla-Gutierrez, Diego Cambrón-Mora, Yeminia Valle
International Journal of Molecular Sciences. 2021; 22(13): 7106
[Pubmed] | [DOI]
68 Therapeutic Potential of Jasmonic Acid and Its Derivatives
Iwona Jarocka-Karpowicz, Agnieszka Markowska
International Journal of Molecular Sciences. 2021; 22(16): 8437
[Pubmed] | [DOI]
69 An Insight into Anti-Inflammatory Activities and Inflammation Related Diseases of Anthocyanins: A Review of Both In Vivo and In Vitro Investigations
Zilong Ma, Bin Du, Jun Li, Yuedong Yang, Fengmei Zhu
International Journal of Molecular Sciences. 2021; 22(20): 11076
[Pubmed] | [DOI]
70 The Role of the Immune System in IBD-Associated Colorectal Cancer: From Pro to Anti-Tumorigenic Mechanisms
Sofía Frigerio, Dalia A. Lartey, Geert R. D’Haens, Joep Grootjans
International Journal of Molecular Sciences. 2021; 22(23): 12739
[Pubmed] | [DOI]
71 Receptor-Interacting Serine/Threonine-Protein Kinase-2 as a Potential Prognostic Factor in Colorectal Cancer
Rola F. Jaafar, Zeid Ibrahim, Karim Ataya, Joelle Hassanieh, Natasha Ard, Walid Faraj
Medicina. 2021; 57(7): 709
[Pubmed] | [DOI]
72 Jasmonate Compounds and Their Derivatives in the Regulation of the Neoplastic Processes
Iwona Jarocka-Karpowicz, Agnieszka Markowska
Molecules. 2021; 26(10): 2901
[Pubmed] | [DOI]
73 Sweet Cherries as Anti-Cancer Agents: From Bioactive Compounds to Function
Lara R. S. Fonseca, Gonçalo R. Silva, Ângelo Luís, Henrique J. Cardoso, Sara Correia, Cátia V. Vaz, Ana P. Duarte, Sílvia Socorro
Molecules. 2021; 26(10): 2941
[Pubmed] | [DOI]
74 New Insights into Molecular Mechanism behind Anti-Cancer Activities of Lycopene
Boon-Peng Puah, Juriyati Jalil, Ali Attiq, Yusof Kamisah
Molecules. 2021; 26(13): 3888
[Pubmed] | [DOI]
75 Targeting Inflammation by Anthocyanins as the Novel Therapeutic Potential for Chronic Diseases: An Update
Aleksandra Kozlowska, Tomasz Dzierzanowski
Molecules. 2021; 26(14): 4380
[Pubmed] | [DOI]
76 New Series of Pyrazoles and Imidazo-Pyrazoles Targeting Different Cancer and Inflammation Pathways
Maria Grazia Signorello, Federica Rapetti, Elda Meta, Adama Sidibè, Olga Bruno, Chiara Brullo
Molecules. 2021; 26(19): 5735
[Pubmed] | [DOI]
77 Anti-Gastritis and Anti-Lung Injury Effects of Pine Tree Ethanol Extract Targeting Both NF-?B and AP-1 Pathways
Seung A Kim, Jieun Oh, Se Rin Choi, Choong Hwan Lee, Byoung-Hee Lee, Mi-Nam Lee, Mohammad Amjad Hossain, Jong-Hoon Kim, Sarah Lee, Jae Youl Cho
Molecules. 2021; 26(20): 6275
[Pubmed] | [DOI]
78 Nutraceuticals and Cancer: Potential for Natural Polyphenols
Jessica Maiuolo, Micaela Gliozzi, Cristina Carresi, Vincenzo Musolino, Francesca Oppedisano, Federica Scarano, Saverio Nucera, Miriam Scicchitano, Francesca Bosco, Roberta Macri, Stefano Ruga, Antonio Cardamone, Annarita Coppoletta, Annachiara Mollace, Francesco Cognetti, Vincenzo Mollace
Nutrients. 2021; 13(11): 3834
[Pubmed] | [DOI]
79 The Impact of Immune Checkpoint-Inhibitors Therapy in Urinary Bladder Cancer
Ana Lúcia Silva, Pedro Abreu-Mendes, Diana Martins, Fernando Mendes
Onco. 2021; 1(1): 3
[Pubmed] | [DOI]
80 Nanocarriers as a Tool for the Treatment of Colorectal Cancer
Ana Luiza C. de S. L. Oliveira, Timo Schomann, Lioe-Fee de Geus-Oei, Ellen Kapiteijn, Luis J. Cruz, Raimundo Fernandes de Araújo Junior
Pharmaceutics. 2021; 13(8): 1321
[Pubmed] | [DOI]
81 Exosomes as a New Delivery Vehicle in Inflammatory Bowel Disease
Xiaomei Wang, Guoliang Zhou, Wanwan Zhou, Xin Wang, Xiao Wang, Chenggui Miao
Pharmaceutics. 2021; 13(10): 1644
[Pubmed] | [DOI]
82 Immunomodulatory Activity of Phyllanthus maderaspatensis in LPS-Stimulated Mouse Macrophage RAW 264.7 Cells
Uoorakkottil Ilyas, Deepshikha P. Katare, Punnoth Poonkuzhi Naseef, Mohamed Saheer Kuruniyan, Muhammed Elayadeth-Meethal, Vidhu Aeri
Separations. 2021; 8(9): 129
[Pubmed] | [DOI]
83 Mediators of extracellular matrix degradation and inflammation: A new team of possible biomarkers for oral squamous cell carcinoma stage
Radu Radulescu, Alexandra Totan, Marina Imre, Daniela Miricescu, Andreea Didilescu, Maria Greabu
Experimental and Therapeutic Medicine. 2021; 22(2)
[Pubmed] | [DOI]
84 In vitro assessment of the cytotoxicity and anti-inflammatory properties of a novel dietary supplement
Ionela Popescu, Elena Codrici, Simona Mihai, Cristina-Mihaela Luntraru, Mihaela Neagu, Cristiana Tanase
Experimental and Therapeutic Medicine. 2021; 22(4)
[Pubmed] | [DOI]
85 Hyperinsulinemia in Obesity, Inflammation, and Cancer
Anni M.Y. Zhang, Elizabeth A. Wellberg, Janel L. Kopp, James D. Johnson
Diabetes & Metabolism Journal. 2021; 45(3): 285
[Pubmed] | [DOI]
86 Neutrophil-to-lymphocyte ratio is an independent prognostic marker for feline mammary carcinomas
Gonçalo N. Petrucci, Luís Lobo, Felisbina Queiroga, José Martins, Justina Prada, Isabel Pires, Joaquim Henriques
Veterinary and Comparative Oncology. 2021; 19(3): 482
[Pubmed] | [DOI]
87 Inflammation and Inflammasomes: Pros and Cons in Tumorigenesis
Liliana R. Balahura, Aida Selaru, Sorina Dinescu, Marieta Costache
Journal of Immunology Research. 2020; 2020: 1
[Pubmed] | [DOI]
88 Epidemiology of Bladder Cancer
Kalyan Saginala, Adam Barsouk, John Sukumar Aluru, Prashanth Rawla, Sandeep Anand Padala, Alexander Barsouk
Medical Sciences. 2020; 8(1): 15
[Pubmed] | [DOI]
89 Epidemiology, Staging and Management of Prostate Cancer
Adam Barsouk, Sandeep Anand Padala, Anusha Vakiti, Azeem Mohammed, Kalyan Saginala, Krishna Chaitanya Thandra, Prashanth Rawla, Alexander Barsouk
Medical Sciences. 2020; 8(3): 28
[Pubmed] | [DOI]
90 Andrographolide, an Anti-Inflammatory Multitarget Drug: All Roads Lead to Cellular Metabolism
Rafael Agustín Burgos, Pablo Alarcón, John Quiroga, Carolina Manosalva, Juan Hancke
Molecules. 2020; 26(1): 5
[Pubmed] | [DOI]
91 The Adenosine System at the Crossroads of Intestinal Inflammation and Neoplasia
Vanessa D’Antongiovanni, Matteo Fornai, Carolina Pellegrini, Laura Benvenuti, Corrado Blandizzi, Luca Antonioli
International Journal of Molecular Sciences. 2020; 21(14): 5089
[Pubmed] | [DOI]
92 Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases
Maria K. Skytthe, Jonas Heilskov Graversen, Søren K. Moestrup
International Journal of Molecular Sciences. 2020; 21(15): 5497
[Pubmed] | [DOI]
93 Chemopreventive Effect of Dietary Anthocyanins against Gastrointestinal Cancers: A Review of Recent Advances and Perspectives
K.V. Surangi Dharmawansa, David W. Hoskin, H. P. Vasantha Rupasinghe
International Journal of Molecular Sciences. 2020; 21(18): 6555
[Pubmed] | [DOI]
94 Fucoxanthin, a Marine-Derived Carotenoid from Brown Seaweeds and Microalgae: A Promising Bioactive Compound for Cancer Therapy
Sarah Méresse, Mostefa Fodil, Fabrice Fleury, Benoît Chénais
International Journal of Molecular Sciences. 2020; 21(23): 9273
[Pubmed] | [DOI]
95 Mini Review: Opposing Pathologies in Cancer and Alzheimer's Disease: Does the PI3K/Akt Pathway Provide Clues?
Rachel M. Barker, Jeff M. P. Holly, Kalina M. Biernacka, Shelley J. Allen-Birt, Claire M. Perks
Frontiers in Endocrinology. 2020; 11
[Pubmed] | [DOI]
96 Cytokines/Chemokines: Potential Biomarkers for Non-paraneoplastic Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Jingwen Liu, Lei Liu, Wenting Kang, Gongxin Peng, Di Yu, Qiuying Ma, Yatong Li, Yan Zhao, Lin Li, Feifei Dai, Jiawei Wang
Frontiers in Neurology. 2020; 11
[Pubmed] | [DOI]
97 The Gut Microbiota and Inflammation: An Overview
Zahraa Al Bander, Marloes Dekker Nitert, Aya Mousa, Negar Naderpoor
International Journal of Environmental Research and Public Health. 2020; 17(20): 7618
[Pubmed] | [DOI]
98 Comorbidity in Older Patients Hospitalized with Cancer in Northeast China based on Hospital Discharge Data
Xiao-Min Mu, Wei Wang, Fang-Yi Wu, Yu-Ying Jiang, Ling-ling Ma, Jia Feng
International Journal of Environmental Research and Public Health. 2020; 17(21): 8028
[Pubmed] | [DOI]
99 Dietary Flavonoids in p53—Mediated Immune Dysfunctions Linking to Cancer Prevention
Shoib Sarwar Siddiqui, Sofia Rahman, H.P. Vasantha Rupasinghe, Cijo George Vazhappilly
Biomedicines. 2020; 8(8): 286
[Pubmed] | [DOI]
100 Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells
Rhiane Moody, Kirsty Wilson, Anthony Jaworowski, Magdalena Plebanski
Cancers. 2020; 12(3): 673
[Pubmed] | [DOI]
101 Proteoglycans in the Pathogenesis of Hormone-Dependent Cancers: Mediators and Effectors
George Tzanakakis, Eirini-Maria Giatagana, Andrey Kuskov, Aikaterini Berdiaki, Aristidis Tsatsakis, Monica Neagu, Dragana Nikitovic
Cancers. 2020; 12(9): 2401
[Pubmed] | [DOI]
102 Lactobacillus Attenuate the Progression of Pancreatic Cancer Promoted by Porphyromonas Gingivalis in K-rasG12D Transgenic Mice
Shan-Ming Chen, Li-Jin Hsu, Hsiang-Lin Lee, Ching-Pin Lin, Szu-Wei Huang, Caucasus Jun-Lin Lai, Chia-Wei Lin, Wan-Ting Chen, Yu-Jen Chen, Yu-Chien Lin, Chi-Chieh Yang, Ming-Shiou Jan
Cancers. 2020; 12(12): 3522
[Pubmed] | [DOI]
103 The Role of CDK5 in Tumours and Tumour Microenvironments
Phuong Anh Do, Chang Hoon Lee
Cancers. 2020; 13(1): 101
[Pubmed] | [DOI]
104 Health Impacts of a Traditional Illicit Brew (Kaanga) Consumed in Meru County, Kenya
Atuna Titus Gitari, Osano Aloys, Bakari Chaka, Bulitia Godrick
European Journal of Environment and Public Health. 2020; 5(1): em0065
[Pubmed] | [DOI]
105 Investigation of the neutrophil/lymphocyte and monocyte to high-density lipoprotein cholesterol ratios in differentiated thyroid cancers
Kenan ÇADIRCI, Faruk YILDIZ, Havva KESKIN, Muharrem BAYRAK, Hilal KIZILTUNC OZMEN, Senay ARIKAN DURMAZ, Ayse ÇARLIOGLU
Journal of Health Sciences and Medicine. 2020;
[Pubmed] | [DOI]
106

Dynamic Changes in the Neutrophil-to-Lymphocyte Ratio Predict the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization

Hongyu Wang, Chuyang Lin, Wenzhe Fan, Jiang Zhang, Yingqiang Zhang, Wang Yao, Jiaping Li
Cancer Management and Research. 2020; Volume 12: 3433
[Pubmed] | [DOI]
107 Nano drug delivery systems in upper gastrointestinal cancer therapy
Julia Salapa, Allison Bushman, Kevin Lowe, Joseph Irudayaraj
Nano Convergence. 2020; 7(1)
[Pubmed] | [DOI]
108 Interleukin-1ß und pro-tumorale Inflammation – Zentrale Faktoren bei der Entstehung von Krebserkrankungen
Sebastian Kobold, Martin Reck
Oncology Research and Treatment. 2020; 43(3): 6
[Pubmed] | [DOI]
109 Potent anti-inflammatory Terminalia chebula fruit showed in vitro anticancer activity on lung and breast carcinoma cells through the regulation of Bax/Bcl-2 and caspase-cascade pathways
Anil Khushalrao Shendge, Rhitajit Sarkar, Nripendranath Mandal
Journal of Food Biochemistry. 2020; 44(12)
[Pubmed] | [DOI]
110 Carotenoid isolates of Spondias mombin demonstrate anticancer effects in DMBA-induced breast cancer in Wistar rats through X-linked inhibitor of apoptosis protein (XIAP) antagonism and anti-inflammation
Damilohun Samuel Metibemu, Oluseyi Adeboye Akinloye, Adio Jamiu Akamo, Jude Ogechukwu Okoye, David Ajiboye Ojo, Eric Morifi, Idowu Olaposi Omotuyi
Journal of Food Biochemistry. 2020; 44(12)
[Pubmed] | [DOI]
111 Association between dietary inflammatory index and upper aerodigestive tract cancer risk: A systematic review and dose-response meta-analysis
Jiahao Zhu, Yuxiao Ling, Shuai Mi, Hanzhu Chen, Jiayao Fan, Shaofang Cai, Chunhong Fan, Qing Shen, Yingjun Li
Oral Oncology. 2020; 103: 104587
[Pubmed] | [DOI]
112 Association of interleukin-6 gene polymorphisms with the risk of hepatocellular carcinoma
Pei-Pei An, Li-Na Feng, Xiao-Xue Zhang, Qing-Long Jin
Medicine. 2020; 99(50): e23659
[Pubmed] | [DOI]
113 3a-Angeloyloxy-ent-kaur-16-en-19-oic Acid Isolated from Wedelia trilobata L. Alleviates Xylene-Induced Mouse Ear Edema and Inhibits NF-?B and MAPK Pathway in LPS-Stimulated Macrophages
Jingwen Xu, Lei Zhou, Lianlian Sun, Zhe Wang, Yi Wang, Yihai Wang, Xiangjiu He
Journal of Natural Products. 2020; 83(12): 3726
[Pubmed] | [DOI]
114 Modern menstruation: Is it abnormal and unhealthy?
Norman D. Goldstuck
Medical Hypotheses. 2020; 144: 109955
[Pubmed] | [DOI]
115 Is the presence of lung injury in COVID-19 an independent risk factor for secondary lung cancer?
Shao-Lin Tao, Xue-mei Wang, Yong-geng Feng, Po-ming Kang, Qing-yuan Li, Tian-yu Sun, Qun-you Tan, Bo Deng
Medical Hypotheses. 2020; 143: 110074
[Pubmed] | [DOI]
116 Correlation of D-xylose with severity and morbidity-related factors of COVID-19 and possible therapeutic use of D-xylose and antibiotics for COVID-19
Antony Cheudjeu
Life Sciences. 2020; 260: 118335
[Pubmed] | [DOI]
117 An evaluation on potential anti-inflammatory effects of ß-lapachone
Narmin Mokarizadeh, Pouran Karimi, Hamid Kazemzadeh, Nazila Fathi Maroufi, Saeed Sadigh-Eteghad, Saba Nikanfar, Nadereh Rashtchizadeh
International Immunopharmacology. 2020; 87: 106810
[Pubmed] | [DOI]
118 The P2X7 purinergic receptor: a potential therapeutic target for lung cancer
Qianqian Li, Xiaodi Zhu, Wei Song, Xiaoxiang Peng, Ronglan Zhao
Journal of Cancer Research and Clinical Oncology. 2020; 146(11): 2731
[Pubmed] | [DOI]
119 Secreted protein acidic and rich in cysteine and inflammation: Another homeostatic property?
Abdelaziz Ghanemi, Mayumi Yoshioka, Jonny St-Amand
Cytokine. 2020; 133: 155179
[Pubmed] | [DOI]
120 Mechanisms of NLRP3 priming in inflammaging and age related diseases
Anna Gritsenko, Jack P. Green, David Brough, Gloria Lopez-Castejon
Cytokine & Growth Factor Reviews. 2020; 55: 15
[Pubmed] | [DOI]
121 Oleandrin: A bioactive phytochemical and potential cancer killer via multiple cellular signaling pathways
Nazia Kanwal, Azhar Rasul, Ghulam Hussain, Haseeb Anwar, Muhammad Ajmal Shah, Iqra Sarfraz, Ammara Riaz, Rabia Batool, Muhammad Shahbaz, Arif Hussain, Zeliha Selamoglu
Food and Chemical Toxicology. 2020; 143: 111570
[Pubmed] | [DOI]
122 Resistin: An inflammatory cytokine with multi-faceted roles in cancer
Sarabjeet Kour Sudan, Sachin Kumar Deshmukh, Teja Poosarla, Nicolette Paolaungthong Holliday, Donna Lynn Dyess, Ajay Pratap Singh, Seema Singh
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2020; 1874(2): 188419
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
    Inflammation and...
    Cancer Developme...
    Mechanisms for t...
    Mutagenic Potent...
    Helicobacter Pyl...
    Inflammatory Cel...
    Key Molecular Pl...
    Implications for...
   Conclusion
    References
    Article Figures

 Article Access Statistics
    Viewed19220    
    Printed380    
    Emailed0    
    PDF Downloaded30    
    Comments [Add]    
    Cited by others 122    

Recommend this journal